# Chemoprevention of Oral Premalignant Lesions

> **NCT00036283** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 42 (—)

## Conditions studied

- Precancerous Conditions

## Interventions

- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT00036283
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** 42 (—)
- **Last updated:** 2008-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00036283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00036283, "Chemoprevention of Oral Premalignant Lesions". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00036283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*